Key result
The AGT -217 AA genotype showed a non-significant trend toward increased risk of severe preeclampsia (OR 1.5; 95% CI 0.38-5.84; p=0.57), with a potential 2.23-fold synergistic effect with 704C.
Why the study?
Do AGT -217 G→A and T704C polymorphisms increase the risk of severe preeclampsia in pregnant women?
Case-Control (n=270)
Do AGT -217 G→A and T704C polymorphisms increase the risk of severe preeclampsia in pregnant women?
Odds Ratio: 1.5 (95% CI 0.38–5.84)
p-value: p=0.57
The AGT -217 G→A and T704C variants may synergistically increase the risk of severe preeclampsia, though larger studies are needed to confirm this non-significant trend.
Hypothesis-generating for AGT variants in preeclampsia; larger studies needed to confirm synergy or rule out chance.
BACKGROUND: The rate-limiting step of the renin-angiotensin system is the enzymatic cleavage of angiotensinogen (AGT) by renin. The aims of the present study were to investigate the association between AGT T704C (M235T) and -217 G→A polymorphisms with the risk of preeclampsia and synergistic effects of both polymorphisms on the susceptibility to preeclampsia. METHODS: We studied AGT variants in 170 women with preeclampsia, including 84 women with mild and 86 women with severe forms of preeclampsia, and 100 age and parity matched controls. RESULTS: There was a trend towards increased risk of severe preeclampsia in the presence of -217 AA (odds ratio (OR)=1.5, 95% confidence interval (CI)= 0.38-5.84, p=0.57) and TC+CC genotypes (OR=1.32, 95% CI= 0.67-2.58, p=0.42). However, the interaction of both alleles of -217A and 704C highly increased the risk of severe preeclampsia, by 2.23-fold, although this did not reach statistical significance. The frequency of the CC genotype of the T704C polymorphism in early-onset preeclampsia tended to be higher (35%) compared with that in patients with late-onset preeclampsia (21.7%). CONCLUSIONS: The present study demonstrates that both variants of AGT -217 G→A and T704C might work in synergism to influence the risk of severe preeclampsia, which needs to be confirmed in studies with larger sample size.
No takes yet. Share an insight, caveat, or question.
Shahvaisizadeh et al. (2012) conducted a case-control in Preeclampsia (n=270). AGT -217 G→A and T704C (M235T) variants vs. Age and parity matched controls was evaluated on Severe preeclampsia (OR 1.5, 95% CI 0.38-5.84, p=0.57). The AGT -217 AA genotype showed a non-significant trend toward increased risk of severe preeclampsia (OR 1.5; 95% CI 0.38-5.84; p=0.57), with a potential 2.23-fold synergistic effect with 704C.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: